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Osseous sarcoidosis is an uncommon manifestation, reported in 3–13% of 
patients with sarcoidosis. Although older literature suggested that hands and feet 
are most commonly affected, axial bone involvement may be more common than 
previously reported, since earlier studies relied mostly on plain X-rays, which may 
be less sensitive for axial bone lesions. Newer imaging modalities such as MRI and 
PET/CT scanning have demonstrated a larger incidence of vertebral involvement. 
Bone lesions are commonly asymptomatic and patients who have bone involve-
ment may have higher incidences of multi-organ involvement. Osseous sarcoidosis 
appears to be mainly osteolytic in nature, but the radiographic appearance may 
be indistinguishable from other osteolytic lesions and therefore a biopsy is usu-
ally required to confirm the diagnosis. The histological findings of sarcoidosis in 
the bone are the same as in other tissues of the body. No general consensus exists 
for the treatment of bone sarcoidosis but corticosteroids are the most commonly 
prescribed first-line drugs. Methotrexate is the most widely studied steroid-
sparing agent for sarcoidosis and it has been reported useful for a variety of organ 
symptoms, but especially where there is bone involvement.
Keywords: osteolytic lesions, vertebral involvement, PET/CT, corticosteroids, 
methotrexate
1. Introduction
Bone involvement is reported in approximately 3–13% of patients with sarcoid-
osis [1]. However, its frequency is likely underestimated as it is often asymptomatic 
[2–4]. The pathogenesis of sarcoidosis involving the skeletal system remains 
unknown. Patients with skeletal sarcoidosis usually have multiple bones involved 
and numerous other extra-osseous manifestations [3, 5]. Newer imaging modali-
ties have demonstrated a relative increase in axial involvement [3, 4]. Treatment 
guidelines for skeletal sarcoidosis are lacking and evidence comes primarily from 
retrospective case series and individual case reports [3, 4]. Nonetheless, most 
patients with bone involvement respond well to corticosteroids in combination with 
methotrexate [5].
2. Pathophysiology
The pathogenesis of sarcoidosis specifically involving bone is unclear. Some 
authors have postulated that antigenic particles are spread hematogenously or 
through the lymphatic system, creating granulomas within the bone, bone marrow, 
and other organs [4]. This hypothesis may help to explain the greater frequency 
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of liver, spleen, and extrathoracic lymph node involvement in patients with bone 
sarcoidosis [4]. The mechanisms of osteolysis in sarcoidosis also remain unclear. 
Mechanisms that have been postulated include: high levels of 1,25 (OH)2 D3 activity 
stimulating osteoclastic activity, local granuloma-induced osteoclastic reaction and 
the sarcoid granuloma being a source of an osteoclastic activating factor inducing 
bone resorption. However, none of these hypotheses have been shown to provide a 
satisfactory explanation related to the presence of bone lesions in sarcoidosis [1].
3. Epidemiology
Bone involvement is reported in 3–13% of patients with sarcoidosis, although 
its frequency is likely to be underestimated as it is often asymptomatic [1–3]. 
Imaging modalities such as magnetic resonance imaging (MRI) or positron emis-
sion tomography (PET)/computed tomography (CT) scans appear to identify more 
patients with bone involvement than historically appreciated using conventional 
radiography [6]. However, these imaging modalities are not routinely used for the 
diagnosis of skeletal sarcoidosis and are usually used to characterize organ involve-
ment in systemic sarcoidosis or for the investigation of suspected cancer or fever 
of unknown origin [3, 4, 6]. Skeletal sarcoidosis appears to be more common in 
middle-aged and elderly white women [3, 4]. Zhou and colleagues demonstrated 
that white patients were three times more likely than blacks to have bone sarcoidosis 
while another study of 20 patients with bone sarcoidosis reported that 95% of these 
patients were white. Although this difference may reflect demographic characteris-
tics at their institutions, it raises the possibility of a racial predilection [3, 4].
4. Clinical manifestations
Patients with bone sarcoidosis usually have numerous other extra-osseous mani-
festations and compared to matched cases, bone sarcoidosis patients have more 
multi-organ involvement than controls [3–5]. Patients with skeletal sarcoidosis also 
typically have more than one bone involved [3]. However, osseous involvement 
is frequently asymptomatic and can be incidentally detected in up to half of the 
patients [3, 5].
Skeletal sarcoidosis can involve focal areas of both the appendicular and axial 
skeleton. Pain and swelling are the most common symptoms [1, 3]. Older studies 
found that the hands and feet are most commonly affected, with axial bone involve-
ment rarely reported [1]. However, axial bone involvement may be more common 
than previously reported, since earlier studies relied mostly on plain X-rays, which 
may be less sensitive for axial bone lesions [4]. Newer imaging modalities such 
as MRI and PET/CT scanning have demonstrated a larger incidence of vertebral 
involvement, and a recent retrospective study demonstrated that up to 70 percent 
of patients with skeletal sarcoidosis may have spinal disease [4].
4.1 Axial involvement
Axial sarcoidosis most commonly affects the spine followed by the pelvis [3–5]. 
Vertebral involvement is mostly asymptomatic and underdiagnosed [3]. The disease 
frequently affects the lower thoracic and upper lumbar vertebrae, but the cervical 
spine including the atlantoaxial (C1-C2) joint may also be involved [7, 8]. In symp-
tomatic patients, pain is a prominent feature, especially at the thoracolumbar region 




sarcoidosis, there has been increasing recognition of the greater relative frequency of 
axial involvement. In one series of 20 patients with osseous sarcoid, involvement  
of the axial skeleton, especially the pelvis and lumbar spine, was seen in 90 percent 
of patients but was often asymptomatic [3]. In another study, 3.5 percent of patients 
(64 out of 1802) with sarcoidosis had bone involvement and axial involvement was 
more common than appendicular involvement [4]. Skull sarcoidosis is uncommon 
and a recent systematic review yielded only 22 known cases, all of which were case 
reports [9]. In 35% of these cases, skull sarcoidosis was detected incidentally in 
asymptomatic patients [9].
4.2 Appendicular involvement
The most commonly affected appendicular skeletal sites are the proximal and 
middle phalanges of the hands [1]. With phalangeal involvement, patients can expe-
rience local pain and tenderness in the affected region, which can exhibit swelling, 
reduced function, distortion of fingers, and overlying erythema [3, 5]. The findings 
are often bilateral but asymmetric [1, 3]. There is also frequent involvement of the 
feet [3, 4]. Hand lesions were more common in African Americans in one study, but 
bone involvement overall was more frequent in whites [4].
5. Laboratory findings
Laboratory findings in bone sarcoidosis are generally nonspecific and similar 
to those seen in other forms of systemic sarcoidosis without bone disease [4, 10]. 
However, bone marrow involvement may cause leukopenia [11] and one study 
showed a significantly lower white blood cell (WBC) count in patients with skeletal 
sarcoidosis, compared to sarcoidosis patients without bone involvement [4].
Erythrocyte sedimentation rate (ESR), alkaline phosphatase (ALP), and serum 
calcium are normal in the majority of patients with skeletal sarcoidosis and this may 
reflect a distinct pathophysiology compared to other diseases that affect bones, such 
as Paget’s disease, malignancy, osteoporosis, or osteomalacia [3]. Therefore, skeletal 
sarcoidosis should be considered in sarcoidosis patients who present with spinal and 
pelvic bone lesions, especially among asymptomatic patients with normal serum 
calcium and (ALP) [3].
6. Imaging
A number of changes can be seen using conventional radiographs, MRI, and 
PET/CT in patients with osseous sarcoidosis [4]. Conventional radiographs are 
usually sufficient for evaluation of the hands and feet, but MRI and PET/CT are 
more sensitive for the detection of changes in other parts of the skeleton [4].
6.1 Conventional (plain) radiography
A plain radiograph cannot reliably reflect early bone lesions, only the gross 
changes are clear [12]. Nonetheless, conventional radiography can be used to reveal 
the location of sarcoid bone lesions in the small bones of the hands and feet [10]. 
Classic sarcoid lesions in the small bones of the hands and feet are well character-
ized and diagnosed with conventional radiographs, on which they demonstrate the 
familiar “lacy” lytic appearance. The resulting alignment deformities in the hands 
and feet are often due to pathologic fractures with bone collapse rather than joint 
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abnormalities [13]. Although osseous sarcoidosis appears to be mainly osteolytic 
in nature, osteoblastic lesions have also been reported [12]. Sclerotic changes may 
represent the result of a secondary reaction related to treatment and they are not 
necessarily lesions that have been osteoblastic from the beginning [12].
Other radiographic bone lesions that have been described include diffuse 
marrow infiltration, punched-out lesions, permeative lesions and destructive 
lesions (dactylitis). Diffuse marrow infiltration with absorption and disruption of 
bone trabeculae is more frequently, earlier and accurately identified by bone scan 
than plain radiography. Punched-out lesions are small cortical defects surrounded 
by normal bone, usually seen in relatively unaggressive sarcoidosis, and persist 
indefinitely. Permeative lesions start with tunneling in the cortex of the shafts of 
small bones, followed by remodeling of the cortical and trabecular architecture 
to give a reticular pattern. Destructive lesions include rapidly advancing bone 
involvement with multiple fractures, devitalized cortex, considerable soft tissue 
swelling, but no periosteal reaction such as new bone formation. Destructive 
lesions are rare and seen in <0.2% of cases. More than seventy percent of patients 
can have a combination of lesions [12].
6.2 Radionuclide bone scan
Radionuclide scans appear to pick up the infiltration of sarcoidosis earlier and 
more accurately than radiographs and they successfully demonstrate up to 30% 
more osseous lesions than conventional radiography [12]. However, sarcoidosis 
bone lesions show variable uptake on bone scintigraphy and lesions that are occult 
on technetium-99 m (Tc99m) can demonstrate mild to marked fluorodeoxyglucose 
(FDG) avidity on PET/CT throughout the axial and appendicular skeleton [3].
6.3 PET/CT
A systematic review of the utility of PET imaging to monitor sarcoidosis disease 
activity noted that PET may often detect incidental lesions [14]. However, it is 
currently unclear how often asymptomatic osseous lesions might be incidentally 
detected with PET imaging in sarcoidosis [3]. PET scans in patients with skeletal 
sarcoidosis typically show active metabolism in bone, but no feature can reliably 
distinguish sarcoidosis from malignant lesions, particularly in the spine and pelvis 
and bone biopsies may be required to exclude malignancy [5]. A study from the 
Netherlands of 122 patients with biopsy-proven severe sarcoidosis (defined as 
persistent, unexplained disease-related disabling symptoms) revealed focal bone 
uptake and/or more diffuse bone marrow involvement in more than one-third of 
patients by use of PET/CT scanning, although 94 percent of the lesions were not 
evident on low-dose bone CT [6]. This was much higher than expected according 
to most previous published studies. Moreover, it showed that PET/CT may be an 
excellent modality to detect bone involvement compared with more conventional 
modalities [2, 15]. Also of great interest was the low rate of abnormalities on low-
dose CT. Clear bone lesions on CT were identified in only 2 of the 32 patients with 
PET-detected bone abnormalities. This finding suggests that physiological changes 
may precede morphologic changes [6].
The use of PET to assess the extent of disease can also uncover a suitable location 
for biopsy to obtain histological evidence for the diagnosis [6]. Furthermore, assess-
ment of inflammatory activity is helpful to monitor the course of the disease and 
guide therapeutic strategies, but establishing the presence of inflammatory activity 
can be a challenge for clinicians. In recent years, PET has been shown to be a very 




and quantifying the level of inflammatory and granulomatous reactions that occur 
in the lungs and elsewhere in the body [16, 17]. Several reports have demonstrated 
a significant reduction of FDG uptake after the initiation of treatment in bone 
sarcoidosis patients [3, 6, 18]. An example of a pretreatment and posttreatment PET 
scan of a patient with widespread bone sarcoidosis is shown in Figure 1.
6.4 MRI
MRI may be the most sensitive modality in the detection of axial skeleton, large 
tubular bones and bone marrow involvement in sarcoidosis. Long bone and axial 
skeletal involvement may be occult at conventional radiography but depicted at MR 
imaging, with an appearance that resembles that of osseous metastases [13]. With 
the majority of large tubular bone lesions, there is no MRI evidence of periosteal 
involvement or cortical destruction, although cortical disruption and extraosse-
ous extension are usually seen when small bones are involved. The lack of cortical 
destruction with large-bone lesions might explain why the majority of these lesions 
are radiographically occult and clinically silent. On MRI, granulomatous infiltration 
Figure 1. 
PET/CT scan showing marked improvement after initiation of immunosuppressive therapy with no definitive 
evidence for residual FDG-avid disease (Right), compared to previously demonstrated intense FDG-uptake 
within the lymph nodes above and below the diaphragm, within multiple skeletal lesions and within lesions 
involving the lungs, liver and spleen (Left).
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of the bone marrow results in an abnormal signal. The lesions are most often 
hypointense on T1-weighted imaging, hyperintense on T2-weighted and Short Tau 
Inversion Recovery (STIR) imaging and show enhancement after contrast adminis-
tration [13]. Figure 2 demonstrates contrast enhancing lesions of the skull and C2 
vertebra.
Despite the sensitivity of MRI compared with conventional radiography, osseous 
sarcoidosis lesions cannot be reliably distinguished from metastatic lesions on 
routine MRI [19]. In a comparison of osseous sarcoidosis with osseous metastatic 
lesions, the presence of intra- or perilesional fat, lesional border characteristics (i.e., 
sharply defined, brush-like, or poorly defined), and the presence of an extraosseous 
soft tissue mass, as well as posterior element involvement of spinal changes, were 
indicative of osseous sarcoidosis, but overall had only moderate sensitivity for the 
diagnosis, despite relatively high specificity [19].
MR imaging of sarcoidosis lesions of the small bones also provides information 
not available at radiography, demonstrating marrow lesions that are radiographi-
cally occult, extension of granulomas beyond the cortex, and periosseous soft-
tissue involvement [13]. Large bone lesions can have a variety of appearances, 
Figure 2. 
Post-contrast T1 weighted SPACE sequence with fat saturation demonstrates contrast enhancement of osseous 
lesions of the clivus, occipital bone, and C2 vertebra. MRI demonstrates the C2 lesion involves the vertebral 




including round, cannonball-like intramedullary lesions, confluent irregular mar-
row infiltration, less well-defined discrete lesions with a “starry sky” appearance, 
and patchy, diffuse intramedullary lesions [13].
6.5 CT scan
Computed tomography (CT) scanning is often used to evaluate pulmonary 
or lymph node involvement in sarcoidosis, and bony lesions can be detected on 
these scans. However, CT scan is nonspecific, as is conventional radiography, 
and the sensitivity of CT for osseous sarcoid is lower than MRI or PET/CT [4]. 
On radiography and CT, sarcoidosis bone lesions can be mixed, lytic, or scle-
rotic but may also be undetectable, particularly in the axial skeleton and long 
bones [19].
7. Pathology
The histological findings of sarcoidosis in the bone are the same as in other 
tissues of the body [12]. The lesion of sarcoidosis is a focal, well-defined granuloma 
formed by the accumulation of epithelial cells, multinucleated giant cells, lym-
phocytes, macrophages and fibroblasts. The centre of the granuloma is composed 
of macrophage-derived cells and CD4+ T cells, whereas the periphery of the 
granuloma is composed of a large number of antigen-presenting interdigitating 
macrophages, CD4+ and CD8+ T cells [20, 21]. Figure 3 demonstrates a cluster of 
well-formed, non-necrotising granulomas.
Figure 3. 
Microscopic examination of clivus bone tissue demonstrating a cluster of well-formed, non-necrotising 
granulomas.
Sarcoidosis - New Perspectives
8
8. Diagnosis
In patients with classic skeletal lesions, either on conventional hand radiographs 
or with characteristic lesions detected on MRI or PET/CT, and biopsy-proven 
sarcoidosis in another organ, a biopsy may not be necessary, depending upon the 
clinical context [1, 13]. In one study, non-caseating granulomas were identified in 
all thirty-five patients with a positive MRI or PET/CT who underwent bone biopsy 
[3]. This observation might suggest that pathological confirmation may not be 
required for patients with typical imaging patterns [5].
However, because it is not possible to reliably distinguish granulomatous 
bone involvement of sarcoidosis from other causes by MRI or other imaging 
modalities, a biopsy is often required [4, 19]. A site appropriate for biopsy should 
be readily identified and this should be guided by imaging and symptoms [4]. 
In those without a prior diagnosis of sarcoidosis, radiologists should include 
sarcoidosis in the differential diagnosis of musculoskeletal disease detected on 
MRI in the appropriate clinical setting and should be alerted that large bone and 
axial skeleton sarcoidosis lesions encountered on MRI might resemble metastatic 
lesions [22, 23].
9. Differential diagnosis
Despite the increased sensitivity of MRI and PET/CT scans compared to con-
ventional radiography, no imaging modality can reliably distinguish the features of 
osseous sarcoidosis and other skeletal pathologies [5, 6, 19].
Major conditions that should be considered in the differential diagnosis of bone 
sarcoidosis include:
Metastatic cancer or hematopoietic malignancy – The bone lesions in sarcoidosis 
can mimic those of metastatic cancer (eg, of the breast or prostate), lymphoma, 
multiple myeloma, or osseous hemangioma [19, 24, 25]. In patients with sarcoidosis 
documented in other organs and tissues and without any evidence of malignancy, it 
may be possible to infer that bone lesions, particularly with characteristic imaging 
changes, are due to sarcoidosis rather than malignancy. However, malignancy and 
sarcoidosis cannot be reliably distinguished on plain radiographs, by MRI [19], or 
on PET/CT. Therefore, a biopsy is often required to make this distinction if there is 
any clinical uncertainty [6].
Infection – Disseminated granulomatous infections like tuberculosis can result 
in focal or multifocal bone lesions. Fungal infections including disseminated cryp-
tococcosis can also cause widespread osteolytic lesions and should be considered, 
particularly in immunosuppressed patients [26]. Serologic testing and/or biopsy 
and culture of the affected area can be performed to exclude infection [27].
Paget’s disease of bone – Sarcoidosis of the long bones may resemble Paget’s 
disease since both disorders are associated with increased uptake on bone scans and 
with lytic and sclerotic lesions on radiography. Unlike Paget’s disease, however, the 
serum alkaline phosphatase (ALP) concentration is usually normal in patients with 
sarcoidosis [3].
10. Treatment
Treatment guidelines for extrapulmonary sarcoidosis are lacking and evidence 
for benefit in patients with osseous sarcoidosis comes primarily from retrospective 




will already be receiving treatment for other disease manifestations when bone dis-
ease is identified or will require therapy for these manifestations if they are newly 
diagnosed [3, 4]. Isolated, asymptomatic bone disease may not require systemic 
immunosuppressive treatment and some cases of spontaneous remission have 
been reported [28, 29]. Nevertheless, corticosteroids remain the most commonly 
prescribed first-line therapy for bone sarcoidosis. Corticosteroids have been shown 
to be very effective in providing symptomatic relief and treatment with these agents 
may also result in radiological improvement [5, 30]. However, some patients may 
have persistent radiological abnormalities despite clinical resolution [30].
Prolonged corticosteroid therapy is associated with long-term complica-
tions and methotrexate or hydroxychloroquine have often been used, usually in 
combination with corticosteroids, in order to allow lower corticosteroid dose [4]. 
Methotrexate is the most widely studied steroid-sparing agent for sarcoidosis and 
it has been reported useful for a variety of organ symptoms but especially where 
there is bone involvement [4, 28]. Most patients with bone sarcoidosis respond well 
to corticosteroids in combination with methotrexate [5]. Figure 1 demonstrates the 
radiological improvement in a patient that received prednisolone and methotrex-
ate. Other second line-agents including azathioprine and third-line treatments such 
as anti-TNF inhibitors are often prescribed for patients with severe sarcoidosis, 
whose disease cannot be controlled by low-dose corticosteroids and may represent 
alternative options, although these are not well studied in bone sarcoidosis [4]. 
However, there is evidence that tumor necrosis factor (TNF) is involved in the 
pathogenesis of sarcoidosis, and there have been reports of successful treatment of 
refractory bone sarcoidosis with anti-TNF agents [3, 4]. In rare cases with irrevers-
ible bone pain, neurological involvement, or pathological fractures, surgery can be 
considered [30].
11. Prognosis
The presence of bone lesions generally implies a more advanced, chronic, and 
severe disorder overall, with more organs and tissues affected by sarcoidosis [2, 15]. 
Nevertheless, most patients with bone sarcoidosis respond well to corticosteroids in 
combination with methotrexate and this usually results in symptomatic improve-
ment [4, 5]. Infrequently, spontaneous remission of skeletal sarcoidosis may also 
occur [29].
12. Conclusion
The incidence of skeletal sarcoidosis is probably underestimated as it is often 
asymptomatic. However, bone involvement in patients with sarcoidosis gener-
ally implies multi-organ and chronic disease. Skeletal sarcoidosis appears to be 
more common in middle-aged and elderly white women and frequently involves 
the spine. Laboratory findings are generally nonspecific and similar to those seen 
in other forms of systemic sarcoidosis without bone involvement. Conventional 
radiographs are usually sufficient for evaluation of the hands and feet, but MRI 
and PET/CT are more sensitive for the detection of changes in other parts of the 
skeleton. Newer imaging modalities are increasingly being used to evaluate skel-
etal involvement in sarcoidosis but most patients still require a biopsy to confirm 
the diagnosis. Although no general consensus exists for the management of bone 
sarcoidosis, the majority of patients respond well to corticosteroids in combination 
with methotrexate.
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